Drug Trial Radar · NCT06981988
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
Last checked: Nov 20, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jun 2025
Primary completion
Aug 2025
Study completion Feb 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the reasonable dosage, efficacy and safety of Linperlisib in combination with rituximab in subjects with relapsed/refractory (R/R) indolent non-hodgkin lymphoma(NHL) in adults.
Conditions
- Relapsed/Refractory Indolent NHL
Interventions
Linperlisib ; RituximabDrug
Linperlisib ; Rituximab
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD (Maximum tolerated dose)of Linperlisib(Stage 1)Time frame: Subjects are evaluated for DLTs during the first 28-day cycle
- RP2/3D(Recommended Phase II/III Dose) of Linperlisib (Stage 1)Time frame: The RP2/3D for Phase 2/3 will be selected at the end of Phase 1b, approximately 2 years
- Complete response rate (CRR) assessed by Investigator(Stage 2)Time frame: up to 5 years
- Progression-free Survival assessed by Investigator (Stage 2)Time frame: up to 5 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.